

The Management of Retinopathy of Prematurity (ROP)

References

- Abbey AM, Besirli CG, Musch DC, et al. Evaluation of screening for retinopathy of prematurity by ROPtool or a lay reader. *Ophthalmology* 2016;123:385–390.
- An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Pre-maturity. *Arch Ophthalmol* 1984;102:1130–1134.
- Aoyama K, Kondou Y, Suzuki Y, et al. Anesthesia protocols for early vitrectomy in former preterm infants diagnosed with aggressive posterior retinopathy of prematurity. *J Anesth* 2010;24:633–638.
- Araz-Ersan B, Kir N, Tuncer S, et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. *Curr Eye Res* 2015;40:585–591.
- Arevalo JF, Maia M, Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. *Br J Ophthalmol* 2008;92:213–216.
- Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. *Br J Ophthalmol* 2014;98:1636–1641.
- Azad R, Chandra P, Khan MA, Darswal A. Role of intravenous fluorescein angiography in early detection and regression of retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus* 2008;45:36–39.
- Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. *Ophthalmology* 2000; 107:324–327.
- Binenbaum G, Ying GS, Quinn GE, et al. The CHOP post-natal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. *Arch Ophthalmol* 2012;130: 1560–1565.
- Byrne MW, Casale P, Garzon M, et al. Pediatric surgeons and anesthesiologists expand the dialogue on the neurotoxicity question, rationale for early and delayed surgeries, and practice changes while awaiting definitive evidence. *J Neurosurg Anesthesiol* 2014;26:391–395.
- Capone A, Diaz-Rohena R, Sternberg P, et al. Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity. *Am J Ophthalmol* 1993;116:444–450.
- Capone A, Trese MT. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments. *Ophthalmology* 2001;108:2068–2070.
- Carneiro AM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. *Acta Ophthalmol* 2012;90:e25–e30.
- Cernichiaro-Espinosa LA, Olguin-Manriquez FJ, Henaine-Berra A, et al. New insights in diagnosis and treatment for Retinopathy of Prematurity. *Int Ophthalmol* 2016;36:751–760.

Chan JJT, Lam CPS, Kwok MKM, et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. *Sci Rep* 2016;6:27082.

Chan RVP, Patel SN, Ryan MC, et al. The global education network for retinopathy of prematurity (Gen-Rop): development, implementation, and evaluation of a novel tele-education system (an American Ophthalmological Society Thesis). *Trans Am Ophthalmol Soc* 2015;113:T21–T226.

Chavala SH, Farsi S, Maldonado R, et al. Insights into advanced retinopathy of prematurity using handheld spectral domain optical coherence tomography imaging. *Ophthalmology* 2009;116:2448–2456.

Chen SN, Lian I, Hwang YC, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. *Retina* 2015;35:667–674.

Coats DK, Miller AM, Brady McCreery KM, et al. Involution of threshold retinopathy of prematurity after diode laser photocoagulation. *Ophthalmology* 2004;111:1894–1898.

Connor TB, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. *J Clin Invest* 1989;83:1661–1666.

Dailey WA, Gryc W, Garg PG, Drenser KA. Frizzled-4 variations associated with retinopathy and intrauterine growth retardation: a potential marker for prematurity and retinopathy. *Ophthalmology* 2015;122:1917–1923.

Dejana E. The role of wnt signaling in physiological and pathological angiogenesis. *Circ Res* 2010;107:943–952.

DeJonge MH, Ferrone PJ, Trese MT. Diode laser ablation for threshold retinopathy of prematurity: short-term structural outcome. *Arch Ophthalmol* 2000;118:365–367.

Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). *Retina* 2010;30:S24–S31.

Drenser K, Girach A, Capone A. A randomized, placebo-controlled study of intravitreal ocriplasmin in pediatric patients scheduled for vitrectomy. *Retina* 2016;36:565–575.

Drenser KA, Dailey W, Vinekar A, et al. Clinical presentation and genetic correlation of patients with mutations affecting the FZD4 gene. *Arch Ophthalmol* 2009;127:1649–1654.

Drenser KA. Anti-angiogenic therapy in the management of retinopathy of prematurity. *Dev Ophthalmol* 2009;44:89–97.

Dubis AM, Subramaniam CD, Godara P, et al. Subclinical macular findings in infants screened for retinopathy of prematurity with spectral-domain optical coherence tomography. *Ophthalmology* 2013;120:1665–1671.

Erol MK, Ozdemir O, Turgut Coban D, et al. Macular findings obtained by spectral domain optical coherence tomography in retinopathy of prematurity. *J Ophthalmol* 2014;6:468653–468657.

Fierson WM, Capone A; American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association of Certified Orthoptists. Tele-medicine for evaluation of retinopathy of prematurity. *Pediatrics* 2015;135:e238–e254.

Fierson WM; American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. *Pediatrics* 2013;131:189–195.

Flick RP, Sprung J, Harrison TE, et al. Perioperative cardiac arrests in children between 1988 and 2005 at a tertiary referral center: a study of 92,881 patients. *Anesthesiology* 2007;106: 226–237.

Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. *Invest Ophthalmol Vis Sci* 2010;51:2388–2392.

Foroozan R, Connolly BP, Tasman WS. Outcomes after laser therapy for threshold retinopathy of prematurity. *Ophthalmology* 2001;108:1644–1646.

Fung THM, Muqit MMK, Mordant DJ, et al. Noncontact high-resolution ultra-wide-field oral fluorescein angiography in premature infants with retinopathy of prematurity. *JAMA Ophthalmol* 2014;132:108–110.

Gologorsky D, Chang JS, Hess DJ, Berrocal AM. Familial exudative vitreoretinopathy in a premature child. *Ophthalmic Surg Lasers Imaging Retina* 2013;44:603–605.

Gonzales CR, Boshra J, Schwartz SD. 25-Gauge pars plicata vitrectomy for stage 4 and 5 retinopathy of prematurity. *Retina* 2006;26:S42–S46.

Govetto A, Virgili G, Menchini F, et al. A systematic review of endophthalmitis after microincisional versus 20-gauge vitrectomy. *Ophthalmology* 2013;120:2286–2291.

Greven C, Tasman W. Scleral buckling in stages 4B and 5 retinopathy of prematurity. *Ophthalmology* 1990;97:817–820.

Guagliano R, Barillà D, Bertone C, et al. Fluorescein angiography-based diagnosis for retinopathy of prematurity: expert-non expert comparison. *Eur J Ophthalmol* 2013;23: 881–886.

Gupta MP, Chan RVP, Anzures R, et al. Practice patterns in retinopathy of prematurity treatment for disease milder than recommended by Guidelines. *Am J Ophthalmol* 2016;163:1–10.

Gursoy H, Bilgec MD, Erol N, et al. The macular findings on spectral-domain optical coherence tomography in premature infants with or without retinopathy of prematurity. *Int Ophthalmol* 2016;36:591–600.

Hardy RJ, Good WV, Dobson V, et al. Multicenter trial of early treatment for retinopathy of prematurity: study design. *Control Clin Trials* 2004;25:311–325.

Hardy RJ, Palmer EA, Dobson V, et al. Risk analysis of prethreshold retinopathy of prematurity. *Arch Ophthalmol* 2003;121:1697–1701.

Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. *J AAPOS* 2014;18:120–123.

Hiraoka M, Takahashi H, Orimo H, et al. Genetic screening of Wnt signaling factors in advanced retinopathy of prematurity. *Mol Vis* 2010;16:2572–2577.

Hirose T, Katsumi O, Mehta MC, Schepens CL. Vision in stage 5 retinopathy of prematurity after retinal reattachment by open-sky vitrectomy. *Arch Ophthalmol* 1993;111: 345–349.

Ho LY, Ho V, Aggarwal H, et al. Management of avascular peripheral retina in older prematurely born infants. *Retina* 2011;31:1248–1254.

Ho LY, Ranchod TM, Drenser KA, et al. Ab interno incision for pediatric vitreoretinal surgery. *Retina* 2010;30:1542–1543.

Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. *Acta Ophthalmol* 2013;91:e74–e75.

Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. *Graefes Arch Clin Exp Ophthalmol* 2008;246: 1061–1063.

Hong YR, Kim YH, Kim SY, et al. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. *Retina* 2015;35: 1772–1777.

Hoppe G, Yoon S, Gopalan B, et al. Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity. *Proc Natl Acad Sci U S A* 2016;113: E2516–E2525.

Hsieh M, Boerboom D, Shimada M, et al. Mice null for Frizzled4 (*Fzd4*^{-/-}) are infertile and exhibit impaired corpora lutea formation and function. *Biol Reprod* 2005;73:1135–1146.

Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. *Arch Ophthalmol* 2012;130:1000–1006.

Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. *Ophthalmology* 2015;122:1008–1015.

International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. *Arch Ophthalmol* 2005;123:991–999.

Jalali S, Kesarwani S, Hussain A. Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program report number 2. *Am J Ophthalmol* 2011;151:719–724.

Jang SY, Choi KS, Lee SJ. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. *J AAPOS* 2010;14:457–459.

John VJ, McClintic JI, Hess DJ, Berrocal AM. Retinopathy of prematurity versus familial exudative vitreoretinopathy: report on clinical and angiographic findings. *Ophthalmic Surg Lasers Imaging Retina* 2016;47:14–19.

Joshi MM, Ciaccia S, Trese MT, Capone A. Posterior hyaloid contracture in pediatric vitreoretinopathies. *Retina* 2006;26: S38–S41.

- Joshi MM, Trese MT, Capone A. Optical coherence tomography findings in stage 4A retinopathy of prematurity: a theory for visual variability. *Ophthalmology* 2006;113:657–660.
- Kaiser RS, Trese MT, Williams GA, Cox MS. Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. *Ophthalmology* 2001;108: 1647–1653.
- Kaloglu C, Cesur I, Bulut HE. Norrin immunolocalization and its possible functions in rat endometrium during the estrus cycle and early pregnancy. *Dev Growth Differ* 2011;53: 887–896.
- Klufas MA, Patel SN, Ryan MC, et al. Influence of fluorescein angiography on the diagnosis and management of retinopathy of prematurity. *Ophthalmology* 2015;122:1601–1608.
- Knöfler M, Pollheimer J. Human placental trophoblast invasion and differentiation: a particular focus on Wnt signaling. *Front Genet* 2013;4:190.
- Kondo H, Kusaka S, Yoshinaga A, et al. Genetic variants of FZD4 and LRP5 genes in patients with advanced retinopathy of prematurity. *Mol Vis* 2013;19:476–485.
- Kong L, Bhatt AR, Demny AB, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. *Invest Ophthalmol Vis Sci* 2015;56:956–961.
- Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. *Br J Ophthalmol* 2008;92:1450–1455.
- Kychenthal A, Dorta P. 25-gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity. *Retina* 2008;28:S65–S68.
- Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. *Retina* 2008;28:S13–S18.
- Lee AC, Maldonado RS, Sarin N, et al. Macular features from spectral-domain optical coherence tomography as an adjunct to indirect ophthalmoscopy in retinopathy of prematurity. *Retina* 2011;31:1470–1482.
- Lepore D, Molle F, Pagliara MM, et al. Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. *Ophthalmology* 2011;118:168–175.
- Ley D, Hansen-Pupp I, Niklasson A, et al. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. *Pediatr Res* 2013;73:68–74.
- Lien R, Yu MH, Hsu KH, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. Hartnett ME, ed. *PLoS One* 2016;11: e0148019.
- Luhmann UFO, Meunier D, Shi W, et al. Fetal loss in homozygous mutant Norrie disease mice: a new role of Norrin in reproduction. *Genesis* 2005;42:253–262.
- Mackenzie F, Ruhrberg C. Diverse roles for VEGF-A in the nervous system. *Development* 2012;139:1371–1380.
- Maldonado RS, O’Connell R, Ascher SB, et al. Spectral-domain optical coherence tomographic assessment of severity of cystoid macular edema in retinopathy of prematurity. *Arch Ophthalmol* 2012;130:569–578.

Marra KV, Yonekawa Y, Papakostas TD, Arroyo JG. Indications and techniques of endoscope assisted vitrectomy. *J Ophthalmic Vis Res* 2013;8:282–290.

Martinez-Castellanos MA, Schwartz S, Hernández-Rojas ML, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. *Retina* 2013; 33:329–338.

Meza PA. Anesthesia for infants and children. In: Hartnett ME, Trese MT, Capone A Jr, Keats BJB, Caputo G, eds. *Pediatric Retina*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014:577–585.

Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. *Ophthalmology* 2016;123: 1845–1855.

Mintz-Hittner HA, Kuffel RR. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. *Retina* 2008; 28:831–838.

Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. *Cochrane Database Syst Rev* 2014;9: CD011230.

Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. *Pediatrics* 2016;137:e20153218.

Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. *Ophthalmology* 2011;118:1227–1228.

Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. *Arch Ophthalmol* 1988;106: 471–479.

Muni RH, Kohly RP, Charonis AC, Lee TC. Retinoschisis detected with handheld spectral-domain optical coherence tomography in neonates with advanced retinopathy of prematurity. *Arch Ophthalmol* 2010;128:57–62.

Nagata M. Therapeutic possibility in retrolental fibroplasia in the premature infant with light coagulation. *Ganka* 1968;10: 719–727.

Ng EYJ, Connolly BP, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. *Ophthalmology* 2002;109:928–934.

Ng EYJ, Lanigan B, O’Keefe M. Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus* 2006;43: 85–90.

Nusse R. Wnt signaling in disease and in development. *Cell Res* 2005;15:28–32.

Oshima Y, Kadonosono K, Yamaji H, et al. Multicenter survey with a systematic overview of acute-onset endophthalmitis after transconjunctival microincision vitrectomy surgery. *Am J Ophthalmol* 2010;150:716–725.

Pandya HK, Faia LJ, Robinson J, Drenser KA. Macular development in aggressive posterior retinopathy of prematurity. *Biomed Res Int* 2015;2015:808639.

Park SW, Jung HH, Heo H. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. *Acta Ophthalmol* 2014;92:810–813.

Parmalee NL, Kitajewski J. Wnt signaling in angiogenesis. *Curr Drug Targets* 2008;9:558–564.

Patel CK, Fung THM, Muqit MMK, et al. Non-contact ultra- widefield imaging of retinopathy of prematurity using the Optos dual wavelength scanning laser ophthalmoscope. *Eye (Lond)* 2013;27:589–596.

Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreal bevacizumab for retinopathy of prematurity. *Arch Ophthalmol* 2012;130:801–802.

Patel SN, Klufas MA, Ryan MC, et al. Color fundus photography versus fluorescein angiography in identification of the macular center and zone in retinopathy of prematurity. *Am J Ophthalmol* 2015;159:950–957.

Paul Chan RV, Williams SL, Yonekawa Y, et al. Accuracy of retinopathy of prematurity diagnosis by retinal fellows. *Retina* 2010;30:958–965.

Quiroz-Mercado H, Martinez-Castellanos MA, Hernández- Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. *Retina* 2008; 28:S19–S25.

Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, et al. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. *Semin Ophthalmol* 2007;22:109–125.

Recchia FM, Capone A. Contemporary understanding and management of retinopathy of prematurity. *Retina* 2004;24: 283–292.

Recchia FM, Recchia CC. Foveal dysplasia evident by optical coherence tomography in patients with a history of retinopathy of prematurity. *Retina* 2007;27:1221–1226.

Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study (ETROP). *Arch Ophthalmol* 2006;124:24–30.

Rezai KA, Elliott D, Ferrone PJ, Kim RW. Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity. *Arch Ophthalmol* 2005;123:621–626.

Robinson J, Capone AJ. Review of the latest treatments for retinopathy of prematurity: laser photocoagulation versus intravitreal bevacizumab in the management of high-risk pre-threshold (type 1) disease. *Expert Rev Ophthalmol* 2015;10:421–430.

Robinson J. Adult retinopathy of prematurity: a 35-year review. *American Society of Retina Specialists Annual Meeting*; August 26, 2013; Toronto, CA.

Salgado CM, Celik Y, VanderVeen DK. Anterior segment complications after diode laser photocoagulation for prethreshold retinopathy of prematurity. *Am J Ophthalmol* 2010;150: 6–9.

Sankar MJ, Sankar J, Mehta M, et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. *Cochrane Database Syst Rev* 2016;2: CD009734.

Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. *Ophthalmology* 2009;116: 2165–2169.

Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. *Am J Ophthalmol* 2012;153:327–333.

Sinha R, Talawar P, Ramachandran R, et al. Perioperative management and post-operative course in preterm infants undergoing vitreo-retinal surgery for retinopathy of prematurity: a retrospective study. *J Anaesthesiol Clin Pharmacol* 2014;30:258–262.

Sinner B, Becke K, Engelhard K. General anaesthetics and the developing brain: an overview. *Anaesthesia* 2014;69: 1009–1022.

Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. *Ophthalmic Surg Lasers Imaging Retina* 2016;47:280–283.

Sonderegger S, Pollheimer J, Knöfler M. Wnt signalling in implantation, decidualisation and placental differentiation—review. *Placenta* 2010;31:839–847.

Sood BG, Madan A, Saha S, et al. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. *Pediatr Res* 2010;67:394–400.

Steward DJ. Preterm infants are more prone to complications following minor surgery than are term infants. *Anesthesiology* 1982;56:304–306.

Suk KK, Berrocal AM, Murray TG, et al. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus* 2010;47:e1–e4.

Tahija SG, Hersetyati R, Lam GC, et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. *Br J Ophthalmol* 2014;98:507–512.

Tasman W. Ten-year follow-up from the CRYO-ROP study. *Arch Ophthalmol* 2001;119:1200–1201.

Thanos A, Yonekawa Y, Todorich B, et al. Spectral-domain optical coherence tomography in older patients with history of retinopathy of prematurity. *Ophthalmic Surg Lasers Imaging Retina* 2016;47:1086–1094.

Thomas BJ, Yonekawa Y, Trese MT. Complete resolution of large retinal fold after transection of retrolental membrane during lens-sparing vitrectomy for retinopathy of prematurity: a 15-year follow-up. *Retin Cases Brief Rep* 2016;10:93–95.

Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol* 2011;56:95–113.

Trese MT, Droste PJ. Long-term postoperative results of a consecutive series of stages 4 and 5 retinopathy of prematurity. *Ophthalmology* 1998;105:992–997.

Vajzovic L, Hendrickson AE, O'Connell RV, et al. Maturation of the human fovea: correlation of spectral-domain optical coherence tomography findings with histology. *Am J Ophthalmol* 2012;154:779–789.

- van der Griend BF, Lister NA, McKenzie IM, et al. Post-operative mortality in children after 101,885 anesthetics at a tertiary pediatric hospital. *Anesth Analg* 2011;112:1440–1447.
- Villegas VM, Capó H, Cavuoto K, et al. Foveal structure- function correlation in children with history of retinopathy of prematurity. *Am J Ophthalmol* 2014;158:508–512.
- Vinekar A, Avadhani K, Sivakumar M, et al. Understanding clinically undetected macular changes in early retinopathy of prematurity on spectral domain optical coherence tomography. *Invest Ophthalmol Vis Sci* 2011;52:5183–5188.
- Vinekar A, Jayadev C, Mangalesh S, et al. Comparing the outcome of single versus multiple session laser photocoagulation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. *Retina* 2015;35:2130–2136.
- Vinekar A, Sivakumar M, Shetty R, et al. A novel technique using spectral-domain optical coherence tomography (Spectralis, SD-OCT+HRA) to image supine non-anaesthetized infants: utility demonstrated in aggressive posterior retinopathy of prematurity. *Eye (Lond)* 2010;24:379–382.
- Wallace DK, Zhao Z, Freedman SF. A pilot study using “ROPtool” to quantify plus disease in retinopathy of prematurity. *J AAPOS* 2007;11:381–387.
- Wang X, Sawada T, Sawada O, et al. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. *Am J Ophthalmol* 2014; 158:738–744.
- Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. *Retina* 2015;35: 675–680.
- Wong RK, Ventura CV, Espiritu MJ, et al. Training fellows for retinopathy of prematurity care: a web-based survey. *J AAPOS* 2012;16:177–181.
- Wong SC, Capone A. Illumination techniques for complex pediatric anterior retinal detachment and associated retrolental plaque. *Retina* 2015;35:1905–1907.
- Wong SC, Capone A. Microplasmin (ocriplasmin) in pediatric vitreoretinal surgery: update and review. *Retina* 2013;33:339–348.
- Wong SC, Lee TC, Heier JS, Ho AC. Endoscopic vitrectomy. *Curr Opin Ophthalmol* 2014;25:195–206.
- Wu WC, Drenser K, Trese M, et al. Retinal phenotype- genotype correlation of pediatric patients expressing mutations in the Norrie disease gene. *Arch Ophthalmol* 2007; 125:225–230.
- Wu WC, Drenser KA, Lai M, et al. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. *Retina* 2008;28:S75–S80.
- Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. *Am J Ophthalmol* 2013; 155:150–158.
- Wu WC, Lai CC, Lin RI, et al. Modified 23-gauge vitrectomy system for stage 4 retinopathy of prematurity. *Arch Ophthalmol* 2011;129:1326–1331.

Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreal bevacizumab injection for retinopathy of prematurity. *JAMA Ophthalmol* 2015;133:391–397.

Wu WC, Shih CP, Wang NK, et al. Choroidal thickness in patients with a history of retinopathy of prematurity. *JAMA Ophthalmol* 2013;131:1451–1458.

Xu Q, Wang Y, Dabdoub A, et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. *Cell* 2004;116:883–895.

Yonekawa Y, Thanos A, Abbey AM, et al. Hybrid 25- and 27-gauge vitrectomy for complex vitreoretinal surgery. *Ophthalmic Surg Lasers Imaging Retina* 2016;47:352–355.

Yonekawa Y, Thomas BJ, Drenser KA, et al. Familial exudative vitreoretinopathy: spectral-domain optical coherence tomography of the vitreoretinal interface, retina, and choroid. *Ophthalmology* 2015;122:2270–2277.

Yonekawa Y, Wu WC, Kusaka S, et al. Immediate sequential bilateral pediatric vitreoretinal surgery: an international multicenter study. *Ophthalmology* 2016;123:1802–1808.

Yonekawa Y, Wu WC, Nitulescu CE, et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. *Retina* 2017; May 3 [Epub ahead of print].

Yoshida I, Shiba T, Taniguchi H, et al. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2014;252:1483–1489.

Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. *Br J Ophthalmol* 2013;97: 454–459.

Zehetner C, Kralinger MT, Modi YS, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. *Acta Ophthalmol* 2015;93:e154–e159.

Zepeda-Romero LC, Oregon-Miranda AA, Lizarraga-Barrón DS, et al. Early retinopathy of prematurity findings identified with fluorescein angiography. *Graefes Arch Clin Exp Ophthalmol* 2013;251:2093–2097.